About ARTHEx
ARTHEx is a company based in Valencia (Spain) founded in 2018. ARTHEx has raised $93.61 million across 9 funding rounds from investors including European Investment Bank, EIT Health and Bpifrance. ARTHEx offers products and services including Anti-miR Therapy. ARTHEx operates in a competitive market with competitors including Jazz Pharmaceuticals, BridgeBio, Spark Therapeutics, Biogen and Alnylam, among others.
- Headquarter Valencia, Spain
- SectorsHealthcare
- Website arthexbiotech.com
- Social LinkedIn X
- Total Equity Funding$93.61M (USD)
in 9 rounds
- Latest Funding Round$40.64M (USD), Series B
Sep 2025
- InvestorsEuropean Investment Bank
& 10 more
Products & Services of ARTHEx
ARTHEx offers a comprehensive portfolio of products and services, including Anti-miR Therapy.
Investigational drug targeting microRNAs for Myotonic Dystrophy treatment
Funding Insights of ARTHEx
ARTHEx has successfully raised a total of $93.61M across 9 strategic funding rounds. The most recent funding activity was a Series B round of $40.64 million completed in September 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $93.61M
- Total Rounds 9
- Last Round Series B — $40.64M
- First Round $1.7M
(Dec 2019)
- Investors Count 11
All 9 funding rounds of ARTHEx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2025 | $40.64M | Series B | – | Bpifrance | |
| May 2023 | $46.36M | Series B | – | Columbus Venture Partners | |
| Mar 2023 | $11.77M | Grant | – | – | |
| Oct 2022 | $2.46M | Grant | – | – | |
| Oct 2022 | – | Series A | – | European Union | – |
| Jul 2020 | $4.91M | Series A | – | Advent France Biotechnology, Invivo Ventures | – |
| Jun 2020 | – | Grant | – | – | |
| Jun 2020 | – | Seed | – | – | – |
| Dec 2019 | $1.7M | Seed | – | Invivo Ventures | – |
11 investors in total: 11 institutional.
Investors in ARTHEx
ARTHEx has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include European Investment Bank, EIT Health and Bpifrance.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Columbus Venture Partners is focused on biotechnology investment funds. | – | columbusvp.com | Valencia, Spain | |
AdBio Partners is engaged in early-stage life sciences investments. | – | adbio.partners | Paris, France | |
Invivo Partners is engaged in venture capital investments for early-stage healthcare companies. | 2019 | invivoventures.es | Barcelona, Spain | |
- | – | soundbioventures.com | - | |
- | – | hadeanventures.com | - | |
Finance and advisory services for infrastructure projects are provided. | 1958 | eib.org | Luxembourg, Luxembourg | |
- | – | adventfb.com | - | |
Healthcare startups are accelerated and incubated through specialized programs. | 2015 | eithealth.eu | Munich, Germany | |
Government-backed foundation focused on technological development | 1973 | cdti.es | Madrid, Spain | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for ARTHEx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ARTHEx
19 people are tracked at ARTHEx (7 in leadership, 12 in board & advisors).
| Name | Role | Group |
|---|---|---|
Pedro Fernández | Operations Director | Leadership |
Beatriz Llamusí | Chief Scientific Officer & Co-Founder | Leadership |
Judith Walker | CMO | Leadership |
Frédéric Legros | Executive Chairman & CEO | Leadership |
Pedro Fernandez Nohales | Director Of Operations | Leadership |
Estefanía Cerro Herreros | Head Of R&d | Leadership |
Maria Rojas | Head Of Clinical Operations | Leadership |
Guillaume Bassez | Board Member | Board & advisors |
Eric Marcusson | Board Member | Board & advisors |
Nicholas Johnson | Board Member | Board & advisors |
Rubén Artero | Co-Founder | Board & advisors |
Ramón Eritja | Board Member | Board & advisors |
Alain Huriez | Board Member | Board & advisors |
Jose Mesa | Board Member | Board & advisors |
Walter Stockinger | Board Member | Board & advisors |
Muthiah Manoharan | Board Member | Board & advisors |
Luís Pareras | Board Member | Board & advisors |
Bibhash Mukhopadhyay | Board Member | Board & advisors |
Eduardo Cunchillos | Scientific Advisor | Board & advisors |
Complete people profiles for ARTHEx
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of ARTHEx
3 dated milestones of ARTHEx across 7 years, from founding to its latest funding, stage changes and deals.
- Founded ARTHEx is founded.
- Funding First funding round of $1.7M.
- Funding Latest funding round, Series B, of $40.6M.
Competitors of ARTHEx
ARTHEx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, BridgeBio, Spark Therapeutics, Biogen and Alnylam, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | – | Therapeutics for genetic diseases are developed through targeted interventions. | |
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. | |
| atai.life | 2018 | Munich, Germany | $386.67M | – | A biopharmaceutical company accelerating innovative mental health treatments. | |
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| ultragenyx.com | 2010 | Novato, United States | $135.1M | 837 | Therapeutics for rare and ultra-rare metabolic diseases are developed. | |
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. |
Detailed competitors of ARTHEx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of ARTHEx
The website of ARTHEx (arthexbiotech.com) receives about 2.4K visits a month.
- Monthly visits2.4K
▲ 6.9% vs previous month
Latest news on Arthex
Complete news archive for ARTHEx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to ARTHEx
10 companies that operate in the same segment as ARTHEx (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about ARTHEx
ARTHEx was founded in 2018 and raised its 1st funding round 1 year after it was founded.
ARTHEx is headquartered in Valencia, Spain. It is registered at Valencia, Valencian Community, Spain.
ARTHEx is a funded company, having raised a total of $93.61M across 9 funding rounds to date. The company's 1st funding round was a Seed of $1.7M, raised on Dec 2019.
ARTHEx was founded in 2018 in Valencia, Spain, within the biotechnology sector. Oligonucleotide-based treatments for neuromuscular disorders are developed, with emphasis on Myotonic Dystrophy. The lead candidate is engineered to block miRNAs that suppress MBNL12 expression, addressing the functional loss of MBNL proteins. Research and development activities are conducted to advance these therapies toward clinical applications.
ARTHEx's top competitors include Jazz Pharmaceuticals, Spark Therapeutics and BridgeBio.
ARTHEx offers Anti-miR Therapy.
ARTHEx has 11 investors. Key investors include European Investment Bank, EIT Health, Bpifrance, European Union, and CDTI.